An Analytical Review of Clinical Negligence Allegations in Prostate Cancer Screening

Introduction

This paper provides an in-depth analysis of the medicolegal issues arising from the case of Mr White, a 59-year-old black man who was diagnosed with advanced prostate cancer and has alleged clinical negligence by his general practitioner (GP) for declining a prostate-specific antigen (PSA) test at the age of 50, a scenario where evidence from a genito-urinary medicine expert witness is often central. Mr White has a strong family history of prostate cancer. The discussion evaluates the clinical context, relevant NHS guidance at the material time, the GP’s duty of care, the criteria for establishing negligence, causation, pertinent legal precedents, and the probable outcome of potential litigation. The analysis is evidence-based, objective, and intended for medical legal professionals.

Case Summary

Mr White, aged 60, is a black man who was recently diagnosed with prostate cancer. He underwent a PSA test at his golf club as part of an awareness campaign, which revealed a markedly elevated PSA level of 21 ng/ml (with normal considered up to 2.5 ng/ml). Subsequent MRI and biopsy confirmed the diagnosis of prostate cancer, staged T3N1M0, with a Gleason score of 4+3=7, indicating locally advanced disease with regional lymph node involvement. He has been offered hormone therapy, chemotherapy, and radiotherapy, but these treatments are unlikely to be curative.

In 2015, aged 50, Mr White requested a PSA test from his GP due to a significant family history of prostate cancer - his father, grandfather, and two uncles had all died of the disease. The GP declined, citing NHS guidance at the time, which did not recommend screening asymptomatic men. Mr White now seeks to pursue a clinical negligence claim, asserting that an earlier test would have enabled an earlier diagnosis and likely curative treatment. According to his urology expert, it is probable that a modest PSA elevation would have been detected in 2015, revealing organ-confined cancer with a 90% chance of cure via surgery.

Clinical Background

Prostate cancer is a prevalent malignancy, especially among older men, with black British men facing a threefold increased risk. Family history is a significant risk factor, with affected first- and second-degree relatives conferring a two- to threefold increased risk. PSA testing is the standard method for early detection, though it is not without limitations, including false positives, overdiagnosis, and the potential for unnecessary interventions. The decision to screen asymptomatic men remains controversial, balancing the benefits of early detection against the risks of over-investigation.

In Mr White’s case, both his strong family history and his ethnicity placed him at very high risk. However, at the time of his request, he was asymptomatic and under 50 years old.

NHS Guidance at the Time

When Mr White made his request (approximately nine years before his diagnosis), NHS guidance did not recommend population-based screening for prostate cancer in asymptomatic men, regardless of family history. The Prostate Cancer Risk Management Programme (PCRMP) provided GPs with information on PSA testing but advised caution due to insufficient evidence of mortality benefit and the risks associated with overdiagnosis. GPs were advised to inform men about the risks and benefits of PSA testing and to offer testing to those who made an informed choice. Routine screening was not advocated, and there was no requirement to offer PSA testing to asymptomatic men solely based on risk factors.

Duty of Care and Standard Practice

GPs owe a duty of care to their patients, which involves acting in accordance with accepted medical practice and exercising reasonable clinical judgement - matters that are routinely assessed by General Practice (GP) expert witnesses in clinical negligence claims. The standard is that of a responsible body of medical opinion, as established in Bolam v Friern Hospital Management Committee [1957] 1 WLR 582. The refinement in Bolitho v City and Hackney Health Authority [1998] AC 232 requires that the professional opinion relied upon is reasonable and logical. At the time, the prevailing standard among UK GPs was not to offer PSA testing to asymptomatic men under 50, even with a family history, unless the patient was fully informed and requested it.

The GP’s refusal was arguably consistent with national guidance and the standard practice of a responsible body of medical practitioners. However, the duty of care also extends to discussing risk factors and supporting informed decision-making.

Causation and Harm

To succeed in a negligence claim, the claimant must establish, on the balance of probabilities, that the alleged breach caused or materially contributed to the harm suffered. In this case, the harm is the delayed diagnosis of locally advanced prostate cancer. Consideration must be given to whether a PSA test at age 45 would have led to earlier detection and a different clinical outcome. Both sides agree that a curable cancer would probably have been identified in 2017.

A Discussion

The central issues in Mr White’s case are whether the GP’s refusal to provide a PSA test constituted a breach of duty and whether this caused the alleged harm. The GP’s actions were in line with NHS guidance and standard practice at the time, which did not recommend screening asymptomatic men, even those at higher risk.

Mr White contends that the guidance did not prohibit PSA testing but recommended that GPs discuss the pros and cons of testing with individuals, which did not occur in his case.

The legal threshold for negligence is high. Unless it can be shown that the GP failed to provide adequate information for informed patient choice or acted outside the bounds of reasonable practice, breach of duty is unlikely to be established. Causation is complicated by the unpredictable progression of prostate cancer and the limitations of PSA testing. Legal precedents indicate that unless it can be demonstrated, on the balance of probabilities, that earlier testing would have altered the outcome, the claim may not succeed.

Key Medicolegal Issues

Standard of Care and NHS Guidance (2015):

In 2015, NHS guidance did not recommend routine PSA screening for asymptomatic men, due to concerns about overdiagnosis and overtreatment. However, best practice required GPs to consider individual risk factors, such as ethnicity and family history, and to discuss the risks and benefits of PSA testing with patients at increased risk. Black men and those with a strong family history are at significantly higher risk, and guidelines (including those from PCRMP) advised that such men should be informed of their risk and offered PSA testing if requested.

Duty of Care and Informed Consent:

The GP owed a duty of care to Mr White to provide information about his heightened risk and to facilitate informed decision-making. Refusing the test outright, without a documented discussion of risks, benefits, and patient preference, may fall below the standard of care expected of a reasonably competent GP in 2015, especially considering the patient’s explicit request and risk profile.

Causation:

The core issue is whether the failure to offer a PSA test in 2015 caused harm. Expert opinion suggests that a PSA test at age 50 would likely have revealed a modest elevation, leading to earlier diagnosis of organ-confined cancer, which would have had a 90% chance of cure through surgery. The current diagnosis is of locally advanced, likely incurable disease, indicating a significant loss of opportunity for cure.

Legal Precedent and Bolam/Bolitho Tests:

The Bolam test considers whether the GP’s actions were supported by a responsible body of medical opinion at the time, while the Bolitho addendum requires that the opinion be logical and defensible. Given Mr White’s specific risk factors and the existence of guidance supporting PSA testing for high-risk, informed patients, a court may find that the GP’s refusal was not supported by responsible or logical medical opinion.

Conclusion

This case illustrates the importance of individualised risk assessment and shared decision-making in cancer screening. Although national guidance did not recommend routine PSA screening, GPs were expected to identify and act upon increased risk in patients such as Mr White. The failure to do so, resulting in a missed opportunity for cure, may constitute clinical negligence.